Sunshine Biopharma reports Q1 2023 revenues of $4.89M, up 2,100% YoY

Sunshine Biopharma Inc.

2023-Q1 EPS reported -$0.08 revenue$4,894,053

Gross revenues of $4,894,053 for Q1 2023, a 2,100% increase over Q1 2022, driven by Nora Pharma acquisition.
Repurchased 445,711 common shares under $2M stock buyback program; shares cancelled, reducing outstanding count to 22,139,921.
Entered research agreement with Jewish General Hospital to advance Adva-27a anticancer compound through IND-enabling studies.
Obtained exclusive worldwide license from University of Arizona for PLpro protease inhibitors of SARS-CoV-2 (COVID-19).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.